Hong Kong SAR

Hong Kong Exchanges and Clearing's derivatives trading revenue hit a record in 2018, helping to lift its profit attributable to shareholders 26% to HK$9.3bn ($1.2bn).

Futu Holdings, parent of Hong Kong-based Futu Securities International, has launched bookbuilding for its potential $130.8m Nasdaq IPO.

Far East Horizon and Asian Development Bank added a bit of life to the dim sum bond market in February, raising Rmb740m ($110.4m) between them. Bankers think looming maturities could give them more business this year.

China Everbright Water has refiled for a potential dual-listing on the main board of the Hong Kong Stock Exchange after its 2018 application expired.

Mainland regional lender Jinshang Bank and China’s in vitro product distributor IVD Medical are seeking the greenlight to float in Hong Kong.

Blackstone, Gaw Capital Partners and Goldman Sachs are in the market seeking a HK$9.7bn ($1.2bn) five year loan to support their purchase of 12 shopping centres in Hong Kong from Link Real Estate Investment Trust.

JP Morgan has boosted its Australia equity capital markets team with the appointment of Mark Bellofiore, a former Goldman Sachs banker, according to a source familiar with the matter.

The Hong Kong Monetary Authority (HKMA) is looking for a new chief executive. Don’t expect it to look very far.

Zhejiang New Century Hotel Management has covered the books for its Hong Kong IPO after hitting the road with a deal that will be worth as much as HK$1.4bn ($178.8m).

Former Bank of China syndicate head Sebastian Ha has joined SPDB International as its head of fixed income.

CStone Pharmaceuticals will list Hong Kong’s first biotech IPO of 2019 next week, getting things moving with a deal that bankers said is a sign of a maturing market after 2018's rush of deals.

There are just five more weeks until the UK is due to leave the European Union. Is now the time for this old China hand to make his return?